Madrigal Pharmaceuticals has delivered very large gains over the past five years, and with fresh drug data in the headlines, the obvious question is whether today's share price can still be explained by its sales base. For anyone tracking Madrigal, the issue is less about the story and more about what buyers are paying for each dollar of current revenue.
- Over 5 years, Madrigal Pharmaceuticals has returned about 4.8x, which puts a lot of weight on whether its current sales level can carry that kind of market value.
- New MAESTRO-NASH trial findings around Rezdiffra and genetic risk variants may support expectations for broader treatment use, which matters directly for how much investors are willing to pay per unit of sales.
- Your read on Madrigal Pharmaceuticals is one view; the desks covering it have another. See what analysts think Madrigal Pharmaceuticals's shares could be worth.
The stock's next move may depend on whether Madrigal Pharmaceuticals' current market price is aligned with what its sales can justify today.
If you like the Madrigal Pharmaceuticals story but want a wider bench of ideas, a focused screen of 36 healthcare AI stocks can give you more starting points for research.
Is Madrigal Pharmaceuticals Still Cheap on Sales?
P/S fits Madrigal Pharmaceuticals because the business is still anchored in commercialising its drug portfolio rather than producing consistent profits. On this measure, the stock trades on a P/S of about 8.2x, which is below the broader biotech industry average of roughly 11.4x and also under the peer group on about 28.3x.
Because the current multiple sits under the more tailored fair P/S level implied by Madrigal Pharmaceuticals' own profile, the market is not pricing the shares at a premium on this yardstick. Despite the fresh MAESTRO-NASH data around Rezdiffra and genetic risk variants lifting the story, buyers are still paying less per dollar of present revenue than the model suggests would be typical for this kind of biotech business. Explore the numbers behind Madrigal Pharmaceuticals's P/S valuation.
The Madrigal Pharmaceuticals Narrative: What Would Justify Today's Price?
Madrigal Pharmaceuticals' valuation puzzle highlights the role of Simply Wall St Narratives, which outline the specific growth, margin and earnings paths that would need to occur for the stock to be worth materially more or less than it is today on the Community page. Instead of leaving you with a single output from a ratio or model, Narratives explain the future that number is tied to so you can track how reality aligns with those assumptions over time.
One of the top community narratives on Madrigal Pharmaceuticals: 15% undervalued
"Heavy reliance on Rezdiffra as a single asset means future performance is acutely vulnerable to either disappointing long-term outcomes in ongoing trials..."
Discover why this Narrative puts Madrigal Pharmaceuticals at 15% undervalued.
An unanswered piece of the Madrigal Pharmaceuticals story
Valuation only covers what the market is paying today, while our checks quietly flagged recent moves by people inside Madrigal Pharmaceuticals itself. The who, how much and what it might signal are still for you to review. See the recent insider selling flagged for Madrigal Pharmaceuticals.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com